Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 3/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | HTR2A | P28223 | 10/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.39 |
| ▸ | DRD1 | P21728 | 1/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.39 |
| ▸ | DRD3 | P35462 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2549374 | 0.82 | KDM4C (0.46) | KDM4CMEN1KMT2AKDM4EALDH1A1 | |
| SCHEMBL27516798 | 0.70 | KDM4C (0.60) | KDM4CMEN1KMT2ASLC6A4NPC1 | |
| SCHEMBL8713421 | 0.69 | LMNA (0.53) | KDM4CMEN1KMT2AKDM4EALDH1A1 | |
| SCHEMBL7289570 | 0.69 | MEN1 (0.40) | KDM4CMEN1KMT2AHTR2ACYP3A4 | |
| SCHEMBL2549016 | 0.69 | KDM4C (0.43) | KDM4CMEN1KMT2AKDM4EALDH1A1 | |
| SCHEMBL17846084 | 0.67 | MEN1 (0.52) | KDM4CMEN1KMT2AALDH1A1CHRM2 | |
| SCHEMBL2549022 | 0.67 | KDM4C (0.46) | KDM4CMEN1KMT2AKDM4EALDH1A1 | |
| SCHEMBL7287147 | 0.67 | HTR2A (0.47) | KDM4CMEN1KMT2AHTR2ACYP3A4 | |
| SCHEMBL7287152 | 0.67 | HTR2A (0.47) | KDM4CMEN1KMT2AHTR2ACYP3A4 | |
| SCHEMBL31120330 | 0.67 | KCNA5 (0.58) | KDM4CMEN1KMT2AHTR2ACYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9682996-B2 | Alpha helix mimetic compositions for treating cancer and other CBP/catenin-mediated diseases and conditions | Prism BioLab Co., Ltd. (JP) | 2017-06-20 | — | — | US | disclosed |
| US-20150376204-A1 | ALPHA HELIX MIMETIC COMPOSITIONS FOR TREATING CANCER AND OTHER CBP/CATENIN-MEDIATED DISEASES AND CONDITIONS | Prism BioLab Co., Ltd. (JP) | 2015-12-31 | — | — | US | disclosed |
| US-9126981-B2 | Alpha helix mimetic compositions for treating cancer and other CBP/catenin-mediated diseases and conditions | Prism BioLab Co., Ltd. (JP) | 2015-09-08 | — | — | US | disclosed |
| US-20140221657-A1 | ALPHA HELIX MIMETIC COMPOSITIONS FOR TREATING CANCER AND OTHER CBP/CATENIN-MEDIATED DISEASES AND CONDITIONS | PRISM BIOLAB CORPORATION (JP) | 2014-08-07 | — | — | US | disclosed |
| US-20110263607-A1 | ALPHA HELIX MIMETICS IN THE TREATMENT OF CANCER | PRISM BIOLAB CORPORATION (JP) | 2011-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263607-A1 | ALPHA HELIX MIMETICS IN THE TREATMENT OF CANCER | COL1A1, HDGF, HCCS | KDM4C 2606/4885MEN1 1160/4885KMT2A 2980/4885 |
| US-20150376204-A1 | ALPHA HELIX MIMETIC COMPOSITIONS FOR TREATING CANCER AND OTHER CBP/CATENIN-MEDIATED DISEASES AND CONDITIONS | CREBBP, CTNNB1, CTNNA1 | KDM4C 1681/4885MEN1 2962/4885KMT2A 1322/4885 |
| US-20140221657-A1 | ALPHA HELIX MIMETIC COMPOSITIONS FOR TREATING CANCER AND OTHER CBP/CATENIN-MEDIATED DISEASES AND CONDITIONS | CREBBP, CTNNB1, CTNNA1 | KDM4C 1681/4885MEN1 2962/4885KMT2A 1322/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.